Plasmodium Vivax Controlled Human Malaria Infection - Progress and Prospects

Overview

Journal Trends Parasitol

Specialty Parasitology

Date 2016 Dec 14

PMID 27956060

Citations 32

Authors

Ruth O Payne

Paul M Griffin

James S McCarthy

Simon J Draper

Affiliations

Soon will be listed here.

Abstract

Modern controlled human malaria infection (CHMI) clinical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to investigate host-pathogen interactions as well as assess potential new prophylactic and therapeutic interventions. However, in recent years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups in Colombia, the USA, and Australia. This review summarizes the published experiences, and examines the advantages and disadvantages of the different models that initiate infection either by mosquito bite or using a blood-stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a platform for early proof-of-concept testing of drugs and vaccines, accelerating the development of novel interventions.

Citing Articles

Culture and transfection: Two major bottlenecks in understanding biology.

Kumari S, Sinha A Front Microbiol. 2023; 14:1144453.

PMID: 37082177 PMC: 10110902. DOI: 10.3389/fmicb.2023.1144453.

The challenges of human malaria infection models for vaccine development.

Roobsoong W, Yadava A, Draper S, Minassian A, Sattabongkot J Front Immunol. 2023; 13:1006954.

PMID: 36685545 PMC: 9849360. DOI: 10.3389/fimmu.2022.1006954.

A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malaria.

Moita D, Maia T, Duarte M, Andrade C, Albuquerque I, Dwivedi A NPJ Vaccines. 2022; 7(1):163.

PMID: 36526627 PMC: 9755804. DOI: 10.1038/s41541-022-00585-8.

Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.

Duthie M, A S Machado B, Badaro R, Kaye P, Reed S Pathogens. 2022; 11(11).

PMID: 36365010 PMC: 9695603. DOI: 10.3390/pathogens11111259.

latent liver infection is characterized by persistent hypnozoites, hypnozoite-derived schizonts, and time-dependent efficacy of primaquine.

Flannery E, Kangwanrangsan N, Chuenchob V, Roobsoong W, Fishbaugher M, Zhou K Mol Ther Methods Clin Dev. 2022; 26:427-440.

PMID: 36092359 PMC: 9418049. DOI: 10.1016/j.omtm.2022.07.016.

References

Duncan C, Draper S . Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg. 2012; 86(4):561-5. PMC: 3403771. DOI: 10.4269/ajtmh.2012.11-0504. View

MCCARTHY V, CLYDE D . Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol. 1977; 41(1):167-71. DOI: 10.1016/0014-4894(77)90142-4. View

McCarthy J, Sekuloski S, Griffin P, Elliott S, Douglas N, Peatey C . A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One. 2011; 6(8):e21914. PMC: 3159571. DOI: 10.1371/journal.pone.0021914. View

Duncan C, Sheehy S, Ewer K, Douglas A, Collins K, Halstead F . Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One. 2011; 6(7):e22271. PMC: 3142129. DOI: 10.1371/journal.pone.0022271. View

Mordmuller B, Supan C, Lee Sim K, Gomez-Perez G, Ospina Salazar C, Held J . Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015; 14:117. PMC: 4371633. DOI: 10.1186/s12936-015-0628-0. View

Herrington D, CLYDE D, Losonsky G, Cortesia M, Murphy J, Davis J . Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 1987; 328(6127):257-9. DOI: 10.1038/328257a0. View

McCarthy J, Griffin P, Sekuloski S, Bright A, Rockett R, Looke D . Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis. 2013; 208(10):1688-94. PMC: 3888148. DOI: 10.1093/infdis/jit394. View

Herrera S, Solarte Y, Jordan-Villegas A, Echavarria J, Rocha L, Palacios R . Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg. 2011; 84(2 Suppl):4-11. PMC: 3032484. DOI: 10.4269/ajtmh.2011.09-0498. View

Spring M, Murphy J, Nielsen R, Dowler M, Bennett J, Zarling S . First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine. 2013; 31(43):4975-83. DOI: 10.1016/j.vaccine.2013.08.007. View

10.

COATNEY H, COOPER W . Studies in human malaria; trials of quinacrine, colchicine (SN 12,080) and quinine against Chesson strain vivax malaria. Am J Hyg. 1949; 50(2):194-9. View

11.

Arevalo-Herrera M, Forero-Pena D, Rubiano K, Gomez-Hincapie J, Martinez N, Lopez-Perez M . Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers. PLoS One. 2014; 9(6):e99754. PMC: 4070897. DOI: 10.1371/journal.pone.0099754. View

12.

Sauerwein R, Roestenberg M, Moorthy V . Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2010; 11(1):57-64. DOI: 10.1038/nri2902. View

13.

Snounou G, Perignon J . Malariotherapy--insanity at the service of malariology. Adv Parasitol. 2013; 81:223-55. DOI: 10.1016/B978-0-12-407826-0.00006-0. View

14.

Roestenberg M, Bijker E, Sim B, Billingsley P, James E, Bastiaens G . Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2012; 88(1):5-13. PMC: 3541746. DOI: 10.4269/ajtmh.2012.12-0613. View

15.

Roestenberg M, de Vlas S, Nieman A, Sauerwein R, Hermsen C . Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J Infect Dis. 2012; 206(3):319-23. DOI: 10.1093/infdis/jis355. View

16.

Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A . Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 1997; 57(4):495-500. DOI: 10.4269/ajtmh.1997.57.495. View

17.

Church L, Le T, Bryan J, Gordon D, Edelman R, Fries L . Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis. 1997; 175(4):915-20. DOI: 10.1086/513990. View

18.

Spring M, Polhemus M, Ockenhouse C . Controlled human malaria infection. J Infect Dis. 2014; 209 Suppl 2:S40-5. DOI: 10.1093/infdis/jiu063. View

19.

Somsak V, Uthaipibull C, Prommana P, Srichairatanakool S, Yuthavong Y, Kamchonwongpaisan S . Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening. Malar J. 2011; 10:291. PMC: 3198988. DOI: 10.1186/1475-2875-10-291. View

20.

Rieckmann K, Beaudoin R, CASSELLS J, Sell K . Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ. 1979; 57 Suppl 1:261-5. PMC: 2395727. View